Impact Partnership Wealth LLC Acquires Shares of 4,578 Merck & Co., Inc. $MRK

Impact Partnership Wealth LLC acquired a new stake in Merck & Co., Inc. (NYSE:MRK) during the 1st quarter, according to its most recent filing with the SEC. The institutional investor acquired 4,578 shares of the company’s stock, valued at approximately $551,000.

A number of other hedge funds have also modified their holdings of the stock. Kingdom Financial Group LLC. bought a new stake in Merck & Co., Inc. in the fourth quarter valued at $25,000. Abound Financial LLC bought a new position in shares of Merck & Co., Inc. during the fourth quarter valued at $26,000. Prosperity Bancshares Inc bought a new position in shares of Merck & Co., Inc. during the fourth quarter valued at $26,000. United Financial Planning Group LLC acquired a new stake in shares of Merck & Co., Inc. in the 3rd quarter valued at $31,000. Finally, High Note Wealth LLC grew its holdings in shares of Merck & Co., Inc. by 58.9% in the 4th quarter. High Note Wealth LLC now owns 294 shares of the company’s stock worth $31,000 after purchasing an additional 109 shares during the last quarter. 76.07% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on MRK shares. Royal Bank Of Canada reiterated an “outperform” rating and set a $142.00 target price on shares of Merck & Co., Inc. in a research report on Monday, March 30th. Weiss Ratings cut shares of Merck & Co., Inc. from a “hold (c+)” rating to a “hold (c)” rating in a research note on Friday, May 15th. UBS Group raised their price objective on shares of Merck & Co., Inc. from $130.00 to $145.00 and gave the stock a “buy” rating in a report on Monday, April 13th. Citigroup initiated coverage on Merck & Co., Inc. in a report on Wednesday, May 6th. They issued a “neutral” rating and a $125.00 target price on the stock. Finally, JPMorgan Chase & Co. increased their price target on Merck & Co., Inc. from $125.00 to $135.00 and gave the stock an “overweight” rating in a research report on Monday, April 6th. One research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and seven have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $131.83.

Merck & Co., Inc. Trading Down 2.5%

MRK opened at $125.30 on Thursday. The company has a current ratio of 1.30, a quick ratio of 1.06 and a debt-to-equity ratio of 1.02. The stock has a market capitalization of $309.46 billion, a PE ratio of 35.29, a PEG ratio of 2.62 and a beta of 0.19. Merck & Co., Inc. has a 1-year low of $76.66 and a 1-year high of $130.29. The firm has a 50-day moving average price of $116.71 and a two-hundred day moving average price of $115.06.

Merck & Co., Inc. (NYSE:MRK) last announced its earnings results on Thursday, April 30th. The company reported ($1.28) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.47) by $0.19. Merck & Co., Inc. had a net margin of 13.59% and a return on equity of 27.55%. The company had revenue of $16.29 billion for the quarter, compared to analyst estimates of $15.85 billion. During the same period in the prior year, the business earned $2.22 earnings per share. Merck & Co., Inc.’s quarterly revenue was up 4.9% on a year-over-year basis. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. As a group, equities analysts anticipate that Merck & Co., Inc. will post 5.19 earnings per share for the current fiscal year.

Merck & Co., Inc. Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, July 8th. Shareholders of record on Monday, June 15th will be issued a dividend of $0.85 per share. The ex-dividend date of this dividend is Monday, June 15th. This represents a $3.40 annualized dividend and a yield of 2.7%. Merck & Co., Inc.’s dividend payout ratio is currently 95.77%.

Trending Headlines about Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Bank of America raised its price target on Merck to $141 from $130 and reiterated a buy rating, citing improved upside potential. Bank of America raises Merck price target
• Positive Sentiment: Scotiabank lifted its price target to $155 from $136 and maintained an outperform rating, signaling stronger confidence in Merck’s valuation and earnings outlook. Scotiabank raises Merck price target
• Positive Sentiment: Erste Group slightly increased its FY2027 EPS estimate for Merck, reflecting modestly improved long-term earnings expectations. Erste Group EPS estimate update
• Positive Sentiment: Merck announced it will hold its second-quarter 2026 sales and earnings conference call on Aug. 4, keeping investors focused on upcoming results and guidance. Merck earnings conference call announcement
• Neutral Sentiment: Merck also hit a new 52-week high following the analyst upgrade, but the stock has since pulled back after its six-day advance, suggesting some profit-taking. Merck sets new 52-week high on analyst upgrade
• Negative Sentiment: U.S. lawmakers launched a national security probe into Merck’s clinical trial activities in China, raising concerns about data protection, oversight, and exposure to politically sensitive trial sites. Merck faces U.S. security probe over China clinical trials
• Negative Sentiment: Broader healthcare weakness also weighed on sentiment, with the sector lower late Tuesday afternoon. Healthcare stocks softer late afternoon

Merck & Co., Inc. Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.